ATE333892T1 - Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen - Google Patents

Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen

Info

Publication number
ATE333892T1
ATE333892T1 AT97906433T AT97906433T ATE333892T1 AT E333892 T1 ATE333892 T1 AT E333892T1 AT 97906433 T AT97906433 T AT 97906433T AT 97906433 T AT97906433 T AT 97906433T AT E333892 T1 ATE333892 T1 AT E333892T1
Authority
AT
Austria
Prior art keywords
biologically active
cationic lipid
receptor ligand
active molecules
facilitated administration
Prior art date
Application number
AT97906433T
Other languages
English (en)
Inventor
Pi-Wan Cheng
Original Assignee
Pi-Wan Cheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pi-Wan Cheng filed Critical Pi-Wan Cheng
Application granted granted Critical
Publication of ATE333892T1 publication Critical patent/ATE333892T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97906433T 1996-02-09 1997-01-29 Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen ATE333892T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1136896P 1996-02-09 1996-02-09

Publications (1)

Publication Number Publication Date
ATE333892T1 true ATE333892T1 (de) 2006-08-15

Family

ID=21750086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906433T ATE333892T1 (de) 1996-02-09 1997-01-29 Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen

Country Status (7)

Country Link
US (1) US6077834A (de)
EP (1) EP0904100B1 (de)
JP (1) JP4512882B2 (de)
AT (1) ATE333892T1 (de)
AU (1) AU2112697A (de)
DE (1) DE69736385T2 (de)
WO (1) WO1997028817A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
WO1997019675A2 (en) * 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
US6803360B1 (en) 1996-12-30 2004-10-12 Georgetown University Compositions and methods for reducing radiation and drug resistance in cells
EP0988030A1 (de) * 1997-06-13 2000-03-29 The Johns Hopkins University Knobby nanosphären
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
DK1166775T3 (da) * 1997-11-19 2010-05-03 Univ Georgetown Målrettet liposomgenafgivelse
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
HK1041498B (en) * 1998-11-19 2011-07-29 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
PT1811036E (pt) * 1999-02-22 2011-07-11 Univ Georgetown Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes
US9034330B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
CA2427916C (en) * 2000-11-03 2012-01-17 The Regents Of The University Of Michigan Surface transfection and expression procedure
WO2002076448A1 (en) * 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
DE60229118D1 (de) * 2001-04-04 2008-11-13 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
RU2537262C2 (ru) * 2009-07-08 2014-12-27 Общество С Ограниченной Ответственностью "Фарма Ген" Молекулярные конъюгаты с поликатионным участком и лигандом для доставки в клетку и ядро клетки днк и рнк
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
WO2014015016A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
EP3538546B1 (de) 2016-11-14 2025-01-08 Novartis AG Zusammensetzungen, methoden und therapeutische verwendungen des fusogenen proteins minion
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
SG11201908052PA (en) 2017-03-13 2019-09-27 Sdg Inc Lipid-based nanoparticles with enhanced stability
JP7699335B2 (ja) * 2021-02-01 2025-06-27 時空化学株式会社 正極活物質、正極材料及び該正極材料を備える二次電池、並びに、正極活物質の製造方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE3916595A1 (de) * 1989-05-22 1990-11-29 Boehringer Mannheim Gmbh Verfahren zur nichtradioaktiven messung der nucleinsaeuresynthese in eukaryontischen zellen
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
CA2134773A1 (en) * 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
AU677216B2 (en) * 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5329029A (en) * 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
JPH09505593A (ja) * 1993-11-24 1997-06-03 メガバイオス・コーポレイション ピペラジンの両親媒性誘導体
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5780052A (en) * 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
JP4338106B2 (ja) * 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション ペプチド増強カチオン脂質トランスフェクション

Also Published As

Publication number Publication date
JP4512882B2 (ja) 2010-07-28
US6077834A (en) 2000-06-20
DE69736385T2 (de) 2007-08-23
DE69736385D1 (de) 2006-09-07
EP0904100A1 (de) 1999-03-31
AU2112697A (en) 1997-08-28
JP2000506519A (ja) 2000-05-30
WO1997028817A1 (en) 1997-08-14
EP0904100B1 (de) 2006-07-26
EP0904100A4 (de) 2002-01-09

Similar Documents

Publication Publication Date Title
ATE333892T1 (de) Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
DE69505677D1 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
ES2082423T3 (es) Dispositivo para la distribucion transcutanea de farmacos.
BG103552A (bg) Терапевтични средства
ATE83653T1 (de) Hautwirksame pharmaka mit liposomen als wirkstofftraeger.
ATE177943T1 (de) Mit polyethylenglycol modifizierte ceramidlipide und liposomen
DK0993831T3 (da) Forbindelser og præparater til tilförsel af aktive stoffer
DE58905028D1 (de) Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel.
EP0687183A4 (de) Synergistische zusammensetzung bestehend aus einem auf cd4-basierendem protein und anti-hiv-1-antikörper, und methoden zu deren verwendung
EA199900553A1 (ru) Чрескожная терапевтическая система
DE69131347D1 (de) Kationische lipide für die intrazelluläre abgabe von biologisch aktiven molekülen
DK0680750T3 (da) Kosmetisk eller farmaceutisk sammensætning til topisk anvendelse
GR3032673T3 (en) Use of an effective quantitiy of active substances for the treatment of mixed skin.
PT768867E (pt) Forma de dosagem para a administracao de droga em formulacao liquida
ATE276742T1 (de) Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
ATE223204T1 (de) Liposomenzusammensetzung
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
DK1112060T3 (da) Doseringsform anvendende flydende formulering
GR3019171T3 (en) System for delivering drug with enhanced bioacceptability.
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
ITMI940610A0 (it) Platino complessi cationici trinucleari ad attivita' antitumorale e composizioni farmaceutiche che li contengono
FR2735132B1 (fr) Medicament polypeptidique modifie, composition et dispositif d'administration par electrotransport le contenant
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
TR199901237T2 (xx) Bir tienilsiklohegzilamin t�revinin tedavide yeni uygulamas�.
ATE295171T1 (de) Analgetische zusammensetzung welche moxonidine und ein opioid-analgetika enthält

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties